Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04310215
Other study ID # CARTISTEM_2019_01
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 3, 2020
Est. completion date June 13, 2022

Study information

Verified date August 2022
Source Hyundai Bioland Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of adding CARTISTEM®(allogenic umbilical cord blood-derived stem cell product) on microfracture, a currently standard treatment for OLT, in patients with talar chondral or osteochondral defect.


Recruitment information / eligibility

Status Completed
Enrollment 102
Est. completion date June 13, 2022
Est. primary completion date June 13, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Talar chondral/osteochondral lesion confirmed by radiographical exam at screening or diagnosis, an AOFAS score of 75 or below 2. Ankle joint pain/stiffness with no response to conservative treatment for more than 12 weeks 3. Ankle joint cartilage injury of defect of ICRS grade ? in MRI 4. Male or female aged more than 18 5. A one-sided lesion 6. Appropriate function of blood clot: PT(INR) < 1.5×ULN, aPTT <1.5×ULN 7. Appropriate renal function: Creatinine = 2.0 ?/?, Proteinuria = trace 8. Appropriate hepatic function: Total bilirubin = 2.0 ?/?, AST/ALT = 100 IU/L 9. No evidence of auto-immune disorder: According to investigator's judgement based on relevent symtom and physical exam, anti-nuclear antibody and anti-thyroglobulin antibody tests are able to performed and confirmed negative (If positive, there are possible cases according to diagnostic opinion of medical department) 10. No surgery or radiotherapy for the same ankle joint within 6 weeks 11. Female patients agreeing with maintenance of contraception* during study period *hormone contraceptive, implants of intrauterine device or intrauterine system, double barrier contraception[Concurrent use of diaphragm or cervical occlusive cap and male condom], surgical sterilisation, etc. 12. No chronic ligament instability more than grade ? (Grade 0: none, Grade ?: 1~5?, Grade?: 5~10?, Grade ?: >10?) 13. Patients agreeing with participation in this study and signed on informed consent by their own will Exclusion Criteria: 1. Degenerative arthritis in ankle(Kellgren Lawrence Grade 3-4) 2. Autoimmune disease 3. Infectious disease need to administration of parenteral antibiotics 4. Myocardial infarction, congestive heart failure, other serious cardiac disorder or uncontrolled resistant hypertension 5. Serious medical disease(Ex. Kidney disease such as chronic renal failure or Glomerulonephritis, etc., acute/chronic liver disease such as liver cirrhosis, fatty liver etc., medical history of malignancy*) *Complete remission status is possible. 6. Pregnancy or breast-feeding 7. Psychiatric history or epilepsy 8. Alcohol abuse 9. Heavy smoker 10. Chronic inflammatory disease such as rheumatoid arthritis 11. Participants other clinical trials within 4 weeks 12. Administration of immunosuppressing agents such as Cyclosporin A or azathioprine within 6 weeks 13. Patients with acute ligament injury and clinically significant chronic ligament instability 14. Patients treated with surgery or cell therapy product for the same disease 15. Patients with hypersensitivity or allergy history to bovine protein, hyaluronic acid and gentamicin 16. Other inappropriate patients determined by the principal investigator

Study Design


Related Conditions & MeSH terms

  • Chondral or Osteochondral Lesion of Talus

Intervention

Biological:
CARTISTEM®
*Stratified randomization by lesion size below 1.5? or more than 1.5? Procedure: Microfracture Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)
Procedure:
Microfracture
*Stratified randomization by lesion size below 1.5? or more than 1.5? 1. Procedure: Microfracture

Locations

Country Name City State
Korea, Republic of Chungnam National University Hospital Daejeon Jung-gu
Korea, Republic of Inha University Hospital Incheon Jung-gu
Korea, Republic of Gangnam Severance Hospital Seoul Gangnam-gu
Korea, Republic of Korea University Guro Hospital Seoul Guro-gu
Korea, Republic of Kyunghee University Medical Center Seoul Dongdaemun-gu
Korea, Republic of Samsung Medical Center Seoul Gangnam-gu

Sponsors (2)

Lead Sponsor Collaborator
Hyundai Bioland Co., Ltd. Medipost Co Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary ICRS-Cartilage Repair Assessment Total Score Arthroscopic evaluation of articular cartilage repair
: The score range from 12(normal) to 1(severely abnormal) where lower scores indicate more severity of injury
Week 48
Secondary ICRS-Cartilage Repair Assessment Overall Grade The grades range from 1(normal) to 4 (severely abnormal) where lower grades indicate more complete repair Week 48
Secondary Improvement degree of Cartilage Repair by MRI Changes in MOCART(Magnetic resonance Observation of Cartilage Repair Tissue) score
: MOCART score is a 9-part and 29-item scoring system, also resulting in a find cartilage repair tissue score between 0 and 100 points. 100 points represent the best imaginable score
Week 0 and 48
Secondary Degree of Functional improvement in FAOS(Foot & Ankle Outcome Score) : FAOS consists in 42 items that cover 5 dimensions (symptoms, pain, activities of daily living, sport and recreation activities, and quality of life. Raw scores of each sub-scales results of the sum of each items. A normalized score (100 indicationg no symptoms and 0 indicating extreame sysmptoms) is calculated for each subscale Week 0, 24 and 48
Secondary Degree of Functional improvement in AOFAS(The American Orthopaedic Foot & Ankle Score) : AOFAS consists in 9 items that can be divided into 3 sub-scales (pain, function and alignment). 100 points of 1 to 100 represent no symptoms or impairments Week 0, 24 and 48
Secondary Degree of Functional improvement in Tegner activity score : Tegner activity represents the highest level of activity on scale of 0 to 10 that you are able to participate in currently . The higher values represent a better outcome Week 0, 24 and 48
Secondary Degree of Quality of Life improvement in SF-36(Short Form Health Survey-36) : SF-36 comprises 36 items divided into two components of physical health and mental health. Higher scores between 0 and 100 represent better health status Week 0, 24 and 48
Secondary Degree of pain improvement in 100 mm VAS(Visual Analogue Scale) VAS represents higher scores mean higher pain
0 mm (no pain) and 100 mm (worst pain)
Week 0, 24 and 48